In the present study, Rokumigan, Hachimijiogan, and Goshajinkigan significantly inhibited glucagon signaling, while the other Kampo drugs used for the purpose of the amelioration of diabetes-related conditions did not. The gene discussed is GCG; the disease is diabetes mellitus.